fda tirzepatide obesity approval for Zepbound (tirzepatide) injection, the first and only treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Zepbound® — A New Treatment

Extensive research continues to underscore the efficacy of semaglutide injections in facilitating weight loss, emphasizing the shift towards treating obesity as a chronic metabolic condition rather than solely relying on lifestyle modifications

The majority of visits involved digestive issuessuch as nausea, vomiting, and diarrheamost often linked to incorrect dosing

Citations Klausen MK et al, "Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial." The Lancet, May 2, 2026

Tambin puede mezclarse con agua

There are only a few studies, but their results thus far seem promising